FHKI conducted its inaugural press conference and symposium for its newly established Group 33 (Biotechnology and Healthcare Council) on 30 April. The event was graced by our officiating Guest of Honour, Algernon Yau, Secretary for Commerce and Economic Development. The Honorable Andrew Leung, President of the Legislative Council and FHKI Honorary President, also joined us together.

FHKI Chairman, Steve Chuang, emphasised the importance of the Council's establishment, noting that it is a testament to the industrial sector's commitment to embracing new industrialisation, “The Biotechnology and Healthcare industries harbour immense potential for development. In recent years, there has been an increasing number of companies within these sectors establishing in Hong Kong; they have also shown immense interest in joining the FHKI. As an international I&T centre, Hong Kong boasts its unique advantage of not only enjoying the strong support of our motherland but also closely connected to the world, making our city an ideal location for science and technology firms to establish headquarters, conduct research, and engage in advanced manufacturing. We will continue to consolidate industry efforts, offer strategic insights to the Government and assist the Biotechnology and Healthcare sector in capitalising on business opportunities, supporting the accelerated development of new productive forces in Hong Kong."

Following the press conference, a symposium "Hong Kong’s Manufacture & Innovation: A New Industrial Path for Biotechnology and Healthcare" took place. Hosted by Prof Jimmy Tao and Ryan Tse, the event featured compelling discussions with leading figures in Hong Kong's biotechnology sector,  including:

  • Prof Dennis Lo, Associate Dean (Research) of the Faculty of Medicine, CUHK
  • Prof Francis Chan, Choh-Ming Li Professor of Medicine & Therapeutics, Faculty of Medicine, CUHK
  • Dr Ricky Chiu, Chairman & CEO of PHASE Scientific International Ltd
  • Prof Terence Lau, Executive Vice President of Avalon Biomedical (Management) Ltd
  • Vivian Tang, Executive Director of Wai Yuen Tong Medicine Holdings Ltd
  • Edmond Yau, Founder & CEO of Koln 3D Technology (Medical) Ltd

In his concluding remarks, Prof Jimmy Tao acknowledged the various challenges facing the Biotechnology and Healthcare industries, such as, high investment costs and long payback periods. However, he expressed confidence in the sectors' potential growth, emphasising the Council's role in uniting industry leaders and its continuous efforts to invite more companies to join. "With our collective expertise, the proven research capabilities in Hong Kong and the international reputation of 'Made in Hong Kong’, we are poised to elevate the entire industry to newer heights," he affirmed.

The newly formed Council encompasses a diverse array of enterprises, including those in biotechnology, biomedical, traditional Chinese medicine, health supplements, and health devices. Its primary objectives are to reflect Hong Kong's evolving industrial landscape, foster sectoral growth, and enhance service delivery to pertinent businesses. 

Contact us